Minerva Neurosciences Investor Relations Material
Latest events
Q1 2023
Minerva Neurosciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Minerva Neurosciences Inc
Access all reports
Minerva Neurosciences Inc is a biopharmaceutical company focused on the development of therapies for central nervous system disorders. The company's research targets conditions such as schizophrenia, depression, and insomnia through proprietary drug candidates. Minerva Neurosciences collaborates with academic and industry partners to advance its clinical programs. The company is headquartered in Burlington, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
NERV
Country
🇺🇸 United States